ITGAX and non-small cell lung carcinoma: DCs represent 2.1% of all immune cells in NSCLC tumors of which plasmocytoid DC (pDC; HLA-DR+CD123+) represent 1.2% of all leukocytes, myeloid DC (mDC2; HLA-DR+CD11c+CD1c+) represent 0.8% and CD141+mDC (mDC1; HLA-DR+CD11c+CD141+) represent 0.1% of all leukocytes (72).